MONTREAL, QUEBEC--(Marketwire - October 04, 2007) - Thallion Pharmaceuticals Inc. (TSX: TLN) announced today that it will be presenting a scientific poster and abstract at the AACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The Company's poster will disclose the pharmacokinetic data from the Phase I/II clinical trial investigating ECO-4601 in advanced cancer patients. The poster session presentations will take place at the Moscone Convention Center West on Wednesday, October 24, from 12:30 pm to 2:30 pm and from 5:30 pm to 7:30 pm. Thallion's poster and abstract, number B-119, are titled: Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent.
